Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUMBA: Rituximab in moderate to severe rheumatoid arthritis
NCT00243412Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2005
- Primary completion
- Feb 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Number of Participants With Either an Infection or a Grade III or IV Adverse Event at 24 months. Started Aug 2005; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00243412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243412.